Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques

Keyphrases

• Rhesus Macaque 100%
• CAR T-cell Therapy 100%
• Chimeric Antigen Receptor T Cells (CAR-T) 100%
• Anti-CD20 Antibody 100%
• Follicle 16%
• Viral Load 11%
• Lymphoid Follicles 11%
• CD20 11%
• Fold Increase 11%
• Anti-CD20 Antibody Treatment 11%
• Dose-escalation Study 5%
• Improved Outcomes 5%
• Lymph Node 5%
• Anti-CD20 5%
• Control Strategy 5%
• Engraftment 5%
• Chronic HIV Infection 5%
• SIV Infection 5%
• Cell Infusion 5%
• Cellular Immunotherapy 5%
• Cell Persistence 5%
• Viral Replication 5%
• CXCR5 5%
• Cell number 5%
• SIVmac239 5%
• Cell Engraftment 5%
• Inflammatory Cytokine Response 5%
• Depletion Study 5%
• Ki-67 5%
• Homing Receptors 5%
• Cell Abundance 5%
• IL-6 Level 5%
• Serum IL-6 5%
• CD20+ Cells 5%

Immunology and Microbiology

• Simian Immunodeficiency Virus 100%
• Rhesus Monkey 100%
• Chimeric Antigen Receptor T-Cell 100%
• CD20 Antibody 100%
• CD20 21%
• Chimeric Antigen Receptor T-Cell Therapy 15%
• Engraftment 10%
• Viral Load 10%
• Lymphatic Follicle 10%
• Human Immunodeficiency Virus 10%
• Viral Replication 5%
• Cytokine Response 5%
• Inflammatory Cytokine 5%
• CD4 5%
• Interleukin 6 5%
• Chemokine Receptor CXCR5 5%
• Lymph Node 5%
• Immunotherapy 5%